MaxCyte will release 2025 financial results on March 24, 2026, followed by a conference call at 4:30 PM ET.
Quiver AI Summary
MaxCyte, Inc. announced that it will release its financial results for the fourth quarter and full year of 2025 on March 24, 2026, after the U.S. market closes. Following the release, company management will host a conference call at 4:30 p.m. Eastern Time to discuss the results, which investors can join by registering online. The company emphasized its commitment to advancing cell-engineering technologies aimed at developing next-generation cell therapeutics. MaxCyte highlights its innovative Flow Electroporation technology and gene editing services that support researchers in creating safer and more effective treatments. The company has been a leader in the field for over 25 years, striving to shape the future of medicine.
Potential Positives
- MaxCyte is set to release its financial results for Q4 and full year 2025, indicating transparency and commitment to shareholder communication.
- The company will host a conference call to discuss its financial results, providing an avenue for direct engagement with investors.
- The focus on cell-engineering technologies positions MaxCyte as a leader in a growing field, highlighting its innovation and potential for future growth.
- The announcement reflects MaxCyte's 25 years of experience in advancing cell engineering, reinforcing its credibility and expertise in the sector.
Potential Negatives
- Financial results being announced after market close may indicate potential concerns regarding performance, as companies typically strive to release results during market hours to allow for immediate analysis.
- The requirement for advance registration to attend the earnings call could limit participation and transparency among interested investors and analysts.
- The lack of preliminary insights or guidance on expected financial performance leading up to the earnings release may raise concerns about the company's operational or financial health.
FAQ
When will MaxCyte announce its 2025 financial results?
MaxCyte will announce its 2025 financial results after U.S. market close on March 24, 2026.
What time is the earnings conference call for MaxCyte?
The earnings conference call will begin at 4:30 p.m. Eastern Time on March 24, 2026.
How can I listen to the MaxCyte conference call?
Interested investors can listen by registering online; it's recommended to register at least one day in advance.
Where can I find the webcast of the earnings call?
A live and archived webcast will be available on the “Events” section of the MaxCyte website.
What technologies does MaxCyte specialize in?
MaxCyte specializes in cell-engineering technologies, including Flow Electroporation® and SeQure DX® gene editing services.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MXCT Revenue
$MXCT had revenues of $6.8M in Q3 2025. This is a decrease of -16.35% from the same period in the prior year.
You can track MXCT financials on Quiver Quantitative's MXCT stock page.
$MXCT Hedge Fund Activity
We have seen 45 institutional investors add shares of $MXCT stock to their portfolio, and 78 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CADIAN CAPITAL MANAGEMENT, LP removed 4,544,551 shares (-55.2%) from their portfolio in Q4 2025, for an estimated $7,044,054
- BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. added 2,773,554 shares (+inf%) to their portfolio in Q4 2025, for an estimated $4,299,008
- MORGAN STANLEY removed 2,262,186 shares (-33.8%) from their portfolio in Q4 2025, for an estimated $3,506,388
- AXA S.A. removed 2,202,378 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $3,479,757
- KENNEDY CAPITAL MANAGEMENT LLC removed 2,107,392 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $3,266,457
- MILLENNIUM MANAGEMENT LLC added 1,183,461 shares (+1082.6%) to their portfolio in Q4 2025, for an estimated $1,834,364
- SILVERCREST ASSET MANAGEMENT GROUP LLC removed 1,074,631 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $1,697,916
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
ROCKVILLE, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the fourth quarter and full year 2025 after the U.S. market close on Tuesday, March 24 th , 2026. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.
Earnings Conference Call Details
Investors interested in listening to the conference call are required to
register online
. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the “Events” section of the MaxCyte website at
https://investors.maxcyte.com/
.
About MaxCyte
At MaxCyte
®
, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation
®
technology and SeQure DX
®
gene editing risk assessment services enable precise, efficient and scalable cell engineering. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers from around the world to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we've been advancing cell engineering, shaping the future of medicine. Learn more at
maxcyte.com
and follow us on
X
and
LinkedIn
.
Investor Relations
Gilmartin Group
David Deuchler, CFA
[email protected]
Media Relations
Oak Street Communications
Kristen White
+1 415-608-6060
[email protected]
